Article

Novel therapeutics in the treatment of bladder cancer.

Department of Urology, Columbia University Medical Center, 161 Fort Washington Avenue, New York, NY 10032, USA.
Current Opinion in Urology (Impact Factor: 2.12). 10/2004; 14(5):287-93. DOI: 10.1097/00042307-200409000-00007
Source: PubMed

ABSTRACT The successful treatment of bladder cancer remains a challenge for urologists and oncologists. There have been substantial changes in the therapeutic options for the management of both superficial and muscle-invasive bladder cancer in the last 5 years. Here we review the preclinical and clinical developments over the last year in bladder cancer therapeutics.
There is a growing trend toward the use of multimodal treatments for all bladder cancers. For superficial disease, intravesical instillation of chemotherapeutic agents after transurethral resection is quickly becoming the standard of care. Novel therapeutic modalities under investigation include DNA vaccines, magnetically targeted carriers, bio-adhesive microspheres and antisense oligodeoxynucleotides. For muscle-invasive bladder cancer, systemic perioperative chemotherapy is being used with increasing frequency and the latest preclinical research efforts are focused on the inhibition of angiogenesis and other processes predisposing to metastatic disease.
Treatment goals for bladder cancer of any stage are complete removal of the initial tumor, prevention of disease recurrence and effective inhibition of progression to advanced disease with the ultimate aim of reducing mortality. The myriad novel therapeutic modalities currently being explored suggest that these goals may perhaps be achievable within our lifetime.

0 Bookmarks
 · 
66 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: HintergrundEinige Publikationen beschreiben einen Benefit für die chirurgische Entfernung von Urothelkarzinommetastasen für ein selektioniertes Krankengut. Wir berichten von den Ergebnissen einer Registerstudie der Arbeitsgemeinschaft Urologische Onkologie (AUOAB30/05) über die Resektion von Urothelkarzinommetastasen in kurativer Absicht. Material und MethodenIn der Zeit zwischen 1991 und 2008 unterzogen sich 44Patienten mit metastasiertem Urothelkarzinom in 15 verschiedenen uroonkologischen Zentren in Deutschland einer kompletten Resektion aller detektierbaren Metastasen mit kurativem Ziel. ErgebnisseDie Lokalisation der entfernten Metastasen teilte sich wie folgt auf: retroperitoneale Lymphknoten (56,8%), andere lymphogene Fernmetastasen (11,3%), Lunge (18,2%), Knochen (4,5%), Nebenniere (2,3%), ZNS (2,3%), Dünndarm (2,3%) und Haut (2,3%). Die Behandlungssequenz beinhaltete eine systemische Chemotherapie vor oder nach der Metastasenresektion bei 35 von 44Patienten (79,5%). Die mediane Überlebenszeit ab initialer Diagnose bzw. ab Resektion der Urothelkarzinommetastasen betrug für das Gesamtüberleben 35 bzw. 27Monate, für das tumorspezifische Überleben 38 und 34Monate und entsprechend für das progressionsfreie Überleben 19 und 15Monate. Die Gesamtüberlebensrate nach 5Jahren betrug 28%. Zum Zeitpunkt der letzten Beobachtung waren 17Patienten ohne weiteren Krankheitsprogress bei einem medianen Follow-up von 8Monaten am Leben. Sieben Patienten ohne Progress überlebten für >2Jahre mit einer medianen Überlebenszeit von 63Monaten. SchlussfolgerungDie Ergebnisse in dieser selektionierten Patientengruppe bestätigen eine langfristige Tumorkontrolle und möglicherweise Heilung in einer Subgruppe von Patienten nach kompletter Resektion von Urothelkarzinommetastasen. Prospektive Daten, um Patienten für diese aggressive Form der Therapie zu identifizieren, liegen nicht vor. Daher verbleibt dieser therapeutische Ansatz weiterhin experimentell und sollte nur Patienten mit einer limitierten Metastasierung unter Einbeziehung systemischer Chemotherapie angeboten werden. BackgroundRecent publications suggest that a subgroup of patients can benefit from surgical removal of transitional cell carcinoma (TCC) metastases in addition to systemic chemotherapy. We report the combined experience and outcome of patients undergoing resection of TCC metastases at 15 uro-oncologic centers in Germany. Materials and MethodsForty-four patients with distant metastatic TCC of the bladder or upper urinary tract underwent resection of all detectable metastases in 15 different German uro-oncological centers between 1991 and 2008 in an attempt to be rendered free of disease. ResultsThe resected metastatic sites consisted of retroperitoneal lymph nodes (56.8%), distant lymph nodes (11.3%), lung (18.2%), bone (4.5%), adrenal gland (2.3%), brain (2.3%), small intestine (2.3%), and skin (2.3%). The treatment sequence included systemic chemotherapy in 35/44 (79.5%) patients before and/or after surgery. Median survival times from initial diagnosis of metastatic TCC and subsequent resection were as follows: overall survival, 35 and 27 months, respectively; cancer-specific survival, 38 and 34 months, respectively; and progression-free survival, 19 and 15 months, respectively. Overall 5-year survival from metastasectomy for the entire cohort was 28%. Seventeen patients were still alive without progression at a median follow-up time of 8 months. Seven patients without disease progression survived for more than 2years and remain free from tumor progression at a median of 63 months. ConclusionThe results in this selected cohort confirm that long-term cancer control and possibly cure can be achieved in a subgroup of patients following surgical removal of TCC metastases. However, prospective data to identify patients most likely to benefit from this aggressive therapeutic approach are lacking. Therefore, metastasectomy in patients with disseminated TCC remains investigational and should be offered only to those with limited disease as a combined-modality approach with systemic chemotherapy.
    Der Urologe 01/2009; 48(2):143-150. · 0.44 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Early-stage bladder cancer occurs as two distinct forms: namely, low-grade superficial disease and high-grade carcinoma in situ (CIS), which is the major precursor of muscle-invasive bladder cancer. Although the low-grade form is readily treatable, few, if any, effective treatments are currently available for preventing progression of nonmuscle-invasive CIS to invasive bladder cancer. Based on our previous findings that the mammalian target of Rapamycin (mTOR) signaling pathway is activated in muscle-invasive bladder cancer, but not superficial disease, we reasoned that suppression of this pathway might block cancer progression. To test this idea, we performed in vivo preclinical studies using a genetically engineered mouse model that we now show recapitulates progression from nonmuscle-invasive CIS to muscle-invasive bladder tumors. We find that delivery of Rapamycin, an mTOR inhibitor, subsequent to the occurrence of CIS effectively prevents progression to invasive bladder cancer. Furthermore, we show that intravesical delivery of Rapamycin directly into the bladder lumen is highly effective for suppressing bladder tumorigenesis. Thus, our findings show the potential therapeutic benefit of inhibiting mTOR signaling for treatment of patients at high risk of developing invasive bladder cancer. More broadly, our findings support a more widespread use of intravesical delivery of therapeutic agents for treatment of high-risk bladder cancer patients, and provide a mouse model for effective preclinical testing of potential novel agents.
    Cancer Prevention Research 12/2009; 2(12):1008-14. · 4.89 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: There is little information on pulmonary metastasectomy of urinary tract transitional cell carcinoma (TCC). In this study, we examined the long-term outcome and the factors associated with long-term survival after pulmonary metastasectomy of urinary tract TCC based on a 20-year single center experience. Between 1984 and 2005, 18 patients (12 men, six women) underwent pulmonary metastasectomy of the urinary tract TCC in our hospital. The clinicopathological and surgical data of these patients obtained from the medical records were analyzed in this retrospective study. The time interval between lung resection and death, or latest follow-up ranged from two to 200 months (median 52). Survival analysis was conducted by the Kaplan-Meier method and log-rank test. The cumulative three- and five-year survival rates were 59.8% and 46.5%, respectively. The number of resected metastatic tumors (solitary vs. multiple) was associated with long-term survival (P<0.05). The five-year survival rate of patients with solitary metastasis was 85.7% while that of patients with multiple metastases was 20.0%. Pulmonary metastasectomy of urinary tract TCC is associated with a favorable outcome, and solitary metastasis is associated with long-term survival. Aggressive management of solitary pulmonary metastasis from a urinary tract TCC is feasible in selected patients.
    Interactive Cardiovascular and Thoracic Surgery 07/2010; 11(1):60-4. · 1.11 Impact Factor